期刊文献+

活血化瘀类中成药合理用药指南(上篇) 被引量:5

Guidelines for rational use of proprietary chinese medicines for promoting blood circulation for removing blood stasis
原文传递
导出
摘要 中医药对血瘀证治疗和活血化瘀类药物的应用具有丰富的理论实践经验,当代活血化瘀治法的广泛应用为重大疾病防治作出了重要贡献。但活血化瘀类中成药的临床应用仍存在应用指征、疗效、作用特点、安全性信息、剂量和疗程等尚不明确的问题,由于不合理用药导致的出血等安全性问题一直受到行业关注。为向中医师、西医师、全科医生及临床药学人员提供科学合理、规范使用活血化瘀中成药的一般原则,本指南编写组遵循循证原则,参考目前高质量临床证据,制定《活血化瘀类中成药合理用药指南》,其中上篇部分包含8项活血化瘀类中成药品种、16项推荐意见,涉及妇科、骨伤科、外科、耳鼻喉科、皮肤科、眼科。 Chinese medicine has rich theoretical and practical experience in the treatment of blood stasis and the application of blood-activating and stasis-removing drugs.The widespread use of contemporary blood-activating and blood-stasis treatment methods has made an important contribution to the prevention and treatment of major diseases.However,the clinical application of blood-activating and stasis-transforming Chinese patent medicines still suffers from unclear application indications,efficacy,action characteristics,safety information,dose and course of treatment,etc.Safety issues such as bleeding caused by irrational use of drugs have been a concern in the industry.To provide traditional Chinese medicine practitioners,Western medicine practitioners,general practitioners and clinical pharmacists with general principles for the scientific,rational and standardized use of blood-activating and blood-stasis-removing proprietary Chinese medicines.This guideline writing group follows the evidence-based principles and makes reference to the current high-quality clinical evidence to develop the“Guidelines for Rational Use of Proprietary Chinese Medicines for Promoting Blood circulation and Removing Blood Stasis”.The upper part contains 8 varieties of blood-activating and stasis-transforming Chinese patent medicines and 16 recommendations,involving gynecology,orthopedics,surgery,otorhinolaryngology,dermatology and ophthalmology.
作者 《活血化瘀类中成药合理用药指南》编写专家组 高蕊 杨忠奇 "Guidelines for Rational Use of Proprietary Chinese Medicines for Promoting Blood circulation and Removing Blood Stasis"Writing Expert Group
出处 《中国新药杂志》 CAS CSCD 北大核心 2023年第4期329-337,I0005,共10页 Chinese Journal of New Drugs
基金 中国中医科学院科技创新工程重大攻关项目:三结合审评证据体系下的中药新药临床评价关键技术研究(CI2021A04701)。
关键词 血瘀证 活血化瘀类中成药 合理用药 指南 blood stasis syndrome activating blood circulation and removing blood stasis class of proprietary Chinese medicines rational use of drugs guidelines
  • 相关文献

参考文献76

二级参考文献645

共引文献723

同被引文献81

引证文献5

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部